The largest number of people who were administrated the COVID-19 vaccine in the Gulf Cooperation Council (GCC) countries in February 2021 was in the United Arab Emirates (UAE) at *** thousand per *********** population.

Get key insights from Market Research Intellect's GCC Countries Polio Vaccines Market Report, valued at USD 150 million in 2024, and forecast to grow to USD 250 million by 2033, with a CAGR of 7.5% (2026-2033).

Explore the rising demand for vaccines for human medicine in the GCC region and how it is expected to drive market growth over the next decade. Market performance is predicted to gradually expand, with a projected increase in market volume to 2.2K tons and market value to $1.3B by 2035.

The United Arab Emirates (UAE) had the highest number of COVID-19 vaccine doses administered at about 134.63 doses per 100 people in June 2021 among other Gulf Cooperation Council (GCC) countries. Among other Gulf Cooperation Council (GCC) countries, Qatar was the only country with a positive fiscal balance before the COVID-19 pandemic.

The article discusses the increasing demand for vaccines for human medicine in GCC, projecting a continual upward consumption trend over the next decade. Market performance is expected to grow at a decelerated rate, with a forecasted CAGR of +1.9% from 2024 to 2035. By the end of 2035, the market volume is estimated to reach 2.2K tons. In terms of value, the market is anticipated to see a CAGR of +3.9% during the same period, reaching a value of $1.3B (in nominal prices) by the end of 2035.

GCC Veterinary Vaccines Market is driven by increasing demand for animal-derived food products, rising pet ownership, and advancements in vaccine technology.

This statistic displays the value of vaccine imports from Saudi Arabia to the Gulf Cooperation Council from 2011 to 2015. In 2015, the value of vaccine imports from Saudi Arabia to the GCC region was about ************* Saudi Arabian Riyal.

In GCC Paediatric Vaccine Market , was valued at approximately USD 10.11 billion in 2022 and is projected to reach USD 12.45 billion by 2029, registering a Compound Annual Growth Rate (CAGR) of 8.65% during the forecast period.

Explore the growth potential of Market Research Intellect's GCC Countries Flu Vaccine (Influenza Vaccine) Market Report, valued at USD 150 million in 2024, with a forecasted market size of USD 250 million by 2033, growing at a CAGR of 7.5% from 2026 to 2033.

Stay updated with Market Research Intellect's GCC Countries TB Vaccines Market Report, valued at USD 150 million in 2024, projected to reach USD 250 million by 2033 with a CAGR of 7.5% (2026-2033).

In GCC Respiratory Disease Vaccine , was valued at approximately USD 10.11 billion in 2022 and is projected to reach USD 12.45 billion by 2029, registering a Compound Annual Growth Rate (CAGR) of 8.65% during the forecast period.

The Middle East and Africa (MEA) cancer vaccines market is experiencing robust growth, projected to reach a significant size by 2033, driven by rising cancer incidence rates, increasing healthcare expenditure, and growing awareness of preventative healthcare measures. A compound annual growth rate (CAGR) of 9.60% from 2019 to 2024 indicates a consistently expanding market. Key drivers include the increasing prevalence of cancers like prostate and cervical cancer, which are significant targets for vaccine development. Furthermore, advancements in vaccine technologies, including recombinant, whole-cell, and viral vector vaccines, are fueling innovation and expanding treatment options. The therapeutic vaccine segment is expected to witness substantial growth due to the increasing demand for effective cancer treatment approaches. However, high vaccine costs, limited healthcare infrastructure in certain regions, and regulatory hurdles pose challenges to market expansion. The GCC region is expected to lead the market due to higher disposable incomes and better healthcare infrastructure compared to other parts of MEA. South Africa represents a significant market within the region due to its relatively developed healthcare system and a substantial cancer patient population. The market is characterized by the presence of both multinational pharmaceutical companies like Astellas Pharma, AstraZeneca, Merck KGaA, GSK, and Bristol-Myers Squibb, and local players catering to the unique needs of the region. Future growth will be significantly influenced by successful clinical trials, regulatory approvals for innovative cancer vaccines, and government initiatives aimed at improving cancer awareness and access to advanced treatment modalities. The segmentation of the MEA cancer vaccines market reveals further insights. The recombinant cancer vaccines segment holds a significant market share owing to their targeted approach and reduced side effects. Preventive vaccines are increasingly gaining traction due to their potential to reduce cancer incidence rates. Within applications, prostate and cervical cancer vaccines dominate the market due to their high prevalence in the region. However, the "Other Applications" segment is also demonstrating growth, reflecting the expanding scope of cancer vaccine research and development. Market penetration will depend on the successful development and launch of new vaccines targeting a wider range of cancers and addressing unmet medical needs. Investment in research and development, coupled with strategic partnerships between pharmaceutical companies and healthcare providers, is crucial for sustained market growth. The market's future hinges on overcoming the limitations presented by cost, infrastructure, and regulatory factors. Stronger public-private collaborations and increased governmental funding will be key catalysts for expanding access to this life-saving technology. Recent developments include: December 2022: Cancer Moonshot publicized new actions aimed at reducing the cancer burden in Africa as part of the United States-Africa Leaders Summit. The Cancer Moonshot highlights bold deliverables and new announcements from U.S. departments and agencies and the private sector of over USD 300 million to drastically improve cancer outcomes in Africa., April 2022: Dante Labs reported that the company was selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines. Dante and the ADSCC will partner on the launch of an R&D program with a focus on personalized treatments for oncology patients and, eventually, the development of cancer vaccines.. Key drivers for this market are: Increasing Number of Cancer Cases, Rise in Research and Developments in Cancer Vaccines. Potential restraints include: Increasing Number of Cancer Cases, Rise in Research and Developments in Cancer Vaccines. Notable trends are: Cervical Cancer Segment is Expected to Witness a Significant Growth in the Market Over the Forecast Period.

The veterinary medicine vaccines market in the GCC region is expected to see a steady increase in demand over the next decade, with a projected growth in market volume to 2.1K tons and market value to $293M by 2035.

The size of the GCC Animal Health Market market was valued at USD 1.37 billion in 2023 and is projected to reach USD 2.58 billion by 2032, with an expected CAGR of 9.45 % during the forecast period. GCC animal health market is the market of services that are associated with the health and welfare of the animals in the member countries of the Gulf Cooperation Council which include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, & UAE. Some of the products that fall under this market are; vaccines, antiretroviral drugs, diagnostic tools, and feed supplements for livestock, poultry, and pets. Disease prevention, treatment and control being the major use is followed by increased animal productivity and food security especially in livestock production. Trends observed in the current world indicate that more and more people are adopting pets and therefore the need for their care and better health, while in the cases of livestock, issues of food security call for the improvement of their health and reproduction. New innovations in diagnose, preventions through vaccination, hyper-filtration in feeds, growth in governmental support for Veterinary infrastructure are helping the market growth. Recent developments include: In February 2024, EQT investment firm acquired Dechra Pharmaceuticals. , In February 2024, Merck Animal Health signed a definitive agreement to acquire Elanco Animal Health's Aqua business. , In May 2023, Zoetis received FDA approval for Librela, which has application in Osteoarthritis (OA) pain , In August 2023, TVG & Australia-based Troy Animal Healthcare extended their product distribution partnership to provide affordable pharmaceuticals for animal care in the GCC region. , In October 2023, Animal Health Directorate of Bahrain launched vaccination programs against foot-and-mouth disease & smallpox in animals. .

The veterinary medicine vaccines market in GCC is expected to experience an upward consumption trend over the next decade, with forecasted growth in volume and value. By 2035, the market is projected to reach 2.1K tons in volume and $293M in value.

GCC Therapeutic Vaccines Market is poised for substantial growth, driven by technological advancements, increasing incidences of chronic diseases.

• The global industry was valued at US$ 21.7 Bn in 2023
• It is projected to grow at a CAGR of -4.3% from 2023 to 2034 and reach more than US$ 9.6 Bn by the end of 2034

Market Introduction

Attribute	Detail
Drivers	Increase in Investments in mRNA Vaccines and Significant Innovations Growth in Emphasis on Cancer Treatment

Regional Outlook of mRNA Vaccine Industry

Attribute	Detail
Leading Region	North America

Global mRNA Vaccine Market Snapshot

Attribute	Detail
Market Value in 2023	US$ 21.7 Bn
Forecast (Value) in 2034	US$ 9.6 Bn
Growth Rate (CAGR)	-4.3%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Mn for Value
Market Analysis	It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2022) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Application COVID-19 Others End-user Government Entities Private Hospitals & Clinics Others (Pharmacies etc.)
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC Countries
Companies Profiled	Pfizer, Inc. Moderna Inc. Novartis AG Sanofi Arcturus Gennova Biopharmaceuticals Ltd Aimei Vaccine Co., Ltd Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

The global sales of attenuated vaccines is estimated to be worth USD 5,068.2 million in 2024 and anticipated to reach a value of USD 9,693.9 million by 2034. Sales are projected to rise at a CAGR of 6.8% over the forecast period between 2024 and 2034. The revenue generated by Attenuated Vaccines in 2023 was USD 4,750.0 million. The industry is anticipated to exhibit a Y-o-Y growth of 6.7% in 2024.

Attributes	Key Insights
Historical Size, 2023	USD 4,750.0 million
Estimated Size, 2024	USD 5,068.2 million
Projected Size, 2034	USD 9,639.9 million
Value-based CAGR (2024 to 2034)	6.7%

Semi Annual Market Update

Particular	Value CAGR
H1	7.5% (2023 to 2033)
H2	7.2% (2023 to 2033)
H1	6.8% (2024 to 2034)
H2	6.3% (2024 to 2034)

Country-wise Insights

Countries	Value CAGR (2024 to 2034)
Canada	3.4%
Argentina	2.4%
France	4.4%
Russia	3.8%
India	5.6%
South Korea	4.2%
GCC Countries	6.1%

Category-wise Insights

Vaccines Type	Monovalent Attenuated Vaccines
Value Share (2024)	54.6%

End Use	Hospitals
Value Share (2034)	35.4%

In 2024, the GCC veterinary medicine vaccines market increased by 12% to $208M, rising for the fourth year in a row after three years of decline. The market value increased at an average annual rate of +5.6% from 2012 to 2024; however, the trend pattern indicated some noticeable fluctuations being recorded in certain years. Over the period under review, the market reached the peak level in 2024 and is expected to retain growth in years to come.

The Middle-East And Africa Cancer Vaccines Market report segments the industry into By Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector And DNA Cancer Vaccines, Other Technologies), By Treatment Method (Preventive Vaccine, Therapeutic Vaccine), By Application (Prostate Cancer, Cervical Cancer, Other Applications), and Geography (GCC, South Africa, Rest Of Middle East And Africa).